Grace Therapeutics Files 8-K
Ticker: GRCE · Form: 8-K · Filed: Oct 23, 2025 · CIK: 1444192
| Field | Detail |
|---|---|
| Company | Grace Therapeutics, INC. (GRCE) |
| Form Type | 8-K |
| Filed Date | Oct 23, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $4.0 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-filing, 8-K, name-change
TL;DR
Grace Therapeutics (fka Acasti Pharma) filed an 8-K on 10/23/25.
AI Summary
Grace Therapeutics, Inc. filed an 8-K on October 23, 2025, reporting other events and financial statements. The company, formerly known as Acasti Pharma Inc. until August 28, 2008, is incorporated in Delaware and headquartered in Princeton, New Jersey.
Why It Matters
This filing indicates ongoing corporate activities and reporting requirements for Grace Therapeutics, Inc., formerly Acasti Pharma Inc.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for corporate reporting and does not disclose any immediate financial or operational risks.
Key Numbers
- 001-35776 — SEC File Number (Identifies the company's filing with the SEC.)
- 98-1359336 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Grace Therapeutics, Inc. (company) — Registrant
- Acasti Pharma Inc. (company) — Former company name
- October 23, 2025 (date) — Date of report
- 001-35776 (company) — SEC File Number
- 98-1359336 (company) — IRS Employer Identification No.
- 103 Carnegie Center Suite 300 Princeton, New Jersey (location) — Principal Executive Offices
FAQ
What specific events are being reported in this 8-K filing?
The filing indicates 'Other Events' and 'Financial Statements and Exhibits' as the items being reported, but the specific details of these events are not provided in the header information.
When did Grace Therapeutics, Inc. change its name from Acasti Pharma Inc.?
The company's name was changed from Acasti Pharma Inc. on August 28, 2008.
Where is Grace Therapeutics, Inc. headquartered?
Grace Therapeutics, Inc. is headquartered at 103 Carnegie Center, Suite 300, Princeton, New Jersey, 08540.
What is the fiscal year end for Grace Therapeutics, Inc.?
The company's fiscal year ends on March 31st.
What is the SIC code for Grace Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Grace Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 517 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2025-10-23 08:09:26
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share GRCE The Nasdaq Stock Mar
- $4.0 million — t the Company has secured approximately $4.0 million in additional funding through exercises
Filing Documents
- ef20057547_8k.htm (8-K) — 29KB
- ef20057547_ex99-1.htm (EX-99.1) — 15KB
- image00002.jpg (GRAPHIC) — 4KB
- 0001140361-25-039020.txt ( ) — 180KB
- grce-20251023.xsd (EX-101.SCH) — 4KB
- grce-20251023_lab.xml (EX-101.LAB) — 21KB
- grce-20251023_pre.xml (EX-101.PRE) — 16KB
- ef20057547_8k_htm.xml (XML) — 4KB
01
Item 8.01. Other Events. On October 23, 2025, Grace Therapeutics, Inc. (the "Company") issued a press release announcing that the Company has secured approximately $4.0 million in additional funding through exercises of common warrants that were previously issued in a private placement that the Company closed in September 2023. The remaining 1,190,927 common warrants issued in the 2023 private placement have expired as the 60th day after the U.S. Food and Drug Administration's acceptance for review of the Company's New Drug Application for GTx-104 has passed. GTx-104 is a clinical-stage, novel, injectable formulation of nimodipine being developed for I.V. infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage patients. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Description 99.1 Press Release, dated October 23 , 2025 . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GRACE THERAPEUTICS, INC. Date: October 23, 2025 By: /s/ Prashant Kohli Prashant Kohli Chief Executive Officer